Dr. Nielsen Discusses the PAM50 Assay

Torsten O. Nielsen, MD, PhD, FRCPC
Published Online: Friday, November 8, 2013
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Most molecular tests, Nielsen says, are very specific for the patient sets from which they were derived and the type of treatment that patients receive. PAM50 is different because it is a biological test that identifies the intrinsic subtypes of breast cancer, Nielsen says. The PAM50 assay is likely to provide relevant information in different types of breast cancer and in different treatment settings.

Nielsen says there are currently clinical trials that are comparing PAM50 with other tests and applying PAM50 to other types of specimens.
Online CME Activities
Free CME from PER
Community Practice Connections: 19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
Addressing Disparities in Care Specific to Patients With Lung Cancer: Health Literacy
Addressing Disparities in Care Specific to Patients With Lung Cancer: Patient Cases
Immunotherapeutic Approaches to the Treatment of Squamous Non-Small Cell Lung Cancer
More Reading
$auto_registration$